

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13G  
(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT  
TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED  
PURSUANT TO RULE 13d-2(b)  
(Amendment No. )<sup>1</sup>

---

Protagonist Therapeutics, Inc.  
(Name of Issuer)

---

Common Stock, \$.00001 par value  
(Title of Class of Securities)

---

74366E102  
(CUSIP Number)

---

August 16, 2016  
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

---

<sup>1</sup> The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

---

1. NAME OF REPORTING PERSON  
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Johnson & Johnson  
EIN: 22-1024240

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]  
(b) [ ]

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

New Jersey

5. SOLE VOTING POWER  
-0-

6. SHARED VOTING POWER  
2,449,183

7. SOLE DISPOSITIVE POWER  
-0-

8. SHARED DISPOSITIVE POWER  
2,449,183

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
2,449,183

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ]

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
15.0%\*

12. TYPE OF REPORTING PERSON  
CO

\* Based on 16,323,551 shares of Common Stock to be outstanding after the completion of the Issuer's initial public offering, as reported in the Issuer's final prospectus relating to its initial public offering filed with the Securities and Exchange Commission on August 12, 2016.

1. NAME OF REPORTING PERSON  
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Johnson & Johnson Innovation-JJDC, Inc.  
EIN: 22-2007137

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]  
(b) [ ]

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

New Jersey

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5. SOLE VOTING POWER
	-0-
	6. SHARED VOTING POWER
	2,449,183
	7. SOLE DISPOSITIVE POWER
	-0-
	8. SHARED DISPOSITIVE POWER
	2,449,183

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
2,449,183

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ]

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
15.0%\*

12. TYPE OF REPORTING PERSON  
CO

\*Based on 16,323,551 shares of Common Stock to be outstanding after the completion of the Issuer's initial public offering, as reported in the Issuer's final prospectus relating to its initial public offering filed with the Securities and Exchange Commission on August 12, 2016.

SCHEDULE 13G

- ITEM 1(a) NAME OF ISSUER:  
Protagonist Therapeutics, Inc.
- ITEM 1(b) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:  
521 Cottonwood Drive, Suite 100  
Malpitas, CA 95035-7404
- ITEM 2(a) NAME OF PERSON FILING:  
This statement is being filed by Johnson & Johnson, a New Jersey corporation ("J&J"), and Johnson & Johnson Innovation-JJDC, Inc., a New Jersey corporation ("JJDC"). JJDC is a wholly-owned subsidiary of J&J. The securities reported herein as being held by J&J and JJDC are directly beneficially owned by JJDC. J&J may be deemed to indirectly beneficially own the securities that are directly beneficially owned by JJDC.
- ITEM 2(b) ADDRESS OF PRINCIPAL BUSINESS OFFICE:  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933
- ITEM 2(c) CITIZENSHIP:  
J&J: New Jersey  
JJDC: New Jersey
- ITEM 2(d) TITLE OF CLASS OF SECURITIES:  
Common Stock, \$.00001 par value per share ("Common Stock")
- ITEM 2(e) CUSIP NUMBER:  
74366E102
- ITEM 3 STATEMENTS FILED PURSUANT TO RULES 13D-1(B) OR 13D-2(B) OR (C):  
Not applicable.

ITEM 4 OWNERSHIP:

The information set forth in Rows 5 through 9 and 11 of the cover pages of this Schedule 13G is incorporated herein by reference.

ITEM 5 OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:

Not applicable.

ITEM 6 OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:

Not applicable.

ITEM 7 IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT COMPANY:

Not applicable.

ITEM 8 IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:

Not applicable.

ITEM 9 NOTICE OF DISSOLUTION OF GROUP:

Not applicable.

ITEM 10 CERTIFICATION:

By signing below the undersigned certify that, to the best of their knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated: August 16, 2016

JOHNSON & JOHNSON

By: /s/ Thomas Spellman III  
Name: Thomas Spellman III  
Title: Secretary

JOHNSON & JOHNSON INNOVATION-JJDC,  
INC.

By: /s/ Steven M. Rosenberg  
Name: Steven M. Rosenberg  
Title: Secretary

